• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Case Report: Primaquine Failure for Radical Cure of Malaria in Gambella, Ethiopia.病例报告:在埃塞俄比亚甘贝拉,伯氨喹根治疟疾失败。
Am J Trop Med Hyg. 2020 Jul;103(1):415-420. doi: 10.4269/ajtmh.19-0890. Epub 2020 May 7.
2
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.从西非感染的间日疟原虫多次复发与 CYP2D6 代谢不良变异体相关:病例报告。
BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.
3
Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.氯喹联合伯氨喹治疗埃塞俄比亚西北部哈马西特地区间日疟原虫疟疾的疗效和安全性。
Malar J. 2024 Jul 6;23(1):202. doi: 10.1186/s12936-024-05031-9.
4
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.在 CYP2D6 功能受损的患者中,正确使用伯氨喹治疗后出现数例间日疟原虫复发。
Malar J. 2020 Jul 17;19(1):259. doi: 10.1186/s12936-020-03326-1.
5
Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.氯喹和氯喹加伯氨喹治疗埃塞俄比亚间日疟原虫的疗效。
Acta Trop. 2010 Feb;113(2):105-13. doi: 10.1016/j.actatropica.2009.10.001. Epub 2009 Oct 14.
6
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.细胞色素 P450 2D6 活性基因型和表型受损与磷酸萘酚喹治疗潜伏性间日疟原虫疟疾的疗效相关性研究。
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
7
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response.在埃塞俄比亚的阿尔巴明奇,不进行 G6PDd 检测,使用氯喹加伯氨喹根治治疗无并发症的间日疟原虫是安全的:临床和寄生虫学反应评估。
Malar J. 2023 Apr 25;22(1):135. doi: 10.1186/s12936-023-04562-x.
8
In vivo efficacy of chloroquine plus primaquine combination therapy against uncomplicated Plasmodium vivax malaria in Limu Kossa District, Jimma Zone, Southwest Ethiopia.在埃塞俄比亚西南部吉马地区利穆科萨区,氯喹加伯氨喹联合疗法治疗无并发症间日疟原虫疟疾的体内疗效。
Malar J. 2024 Oct 8;23(1):300. doi: 10.1186/s12936-024-05124-5.
9
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.新型疟原虫治疗失败见解:CYP2D6 活性和疟疾暴露时间调节复发风险。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02056-19.
10
Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.监测氯喹-伯氨喹疗法对巴西主要传播热点地区无并发症间日疟原虫疟疾的疗效。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.01965-18. Print 2019 May.

引用本文的文献

1
Comparing the diagnostic accuracy of the newly introduced and existing malaria tests in Northwest Ethiopia.比较埃塞俄比亚西北部新引进的疟疾检测方法与现有检测方法的诊断准确性。
PLoS One. 2025 May 7;20(5):e0322366. doi: 10.1371/journal.pone.0322366. eCollection 2025.
2
Analysis of the relapse of imported Plasmodium vivax and Plasmodium ovale in five provinces of China.中国五个省份输入性间日疟原虫和卵形疟原虫的复发分析。
Malar J. 2023 Jul 13;22(1):209. doi: 10.1186/s12936-023-04642-y.
3
Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.间日疟原虫:其对疟疾消除和根除构成的潜在障碍
Trop Dis Travel Med Vaccines. 2022 Dec 15;8(1):27. doi: 10.1186/s40794-022-00185-3.

本文引用的文献

1
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.细胞色素 P450 2D6 活性基因型和表型受损与磷酸萘酚喹治疗潜伏性间日疟原虫疟疾的疗效相关性研究。
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
2
Glucose-6-phosphate dehydrogenase (G6PD) deficiency in Ethiopia: absence of common African and Mediterranean allelic variants in a nationwide study.葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症在埃塞俄比亚:全国性研究中缺乏常见的非洲和地中海等位基因变异。
Malar J. 2018 Oct 26;17(1):388. doi: 10.1186/s12936-018-2538-4.
3
Low and heterogeneous prevalence of glucose-6-phosphate dehydrogenase deficiency in different settings in Ethiopia using phenotyping and genotyping approaches.采用表型和基因型方法在埃塞俄比亚不同环境中葡萄糖-6-磷酸脱氢酶缺乏症的低流行率和异质性。
Malar J. 2018 Aug 2;17(1):281. doi: 10.1186/s12936-018-2437-8.
4
Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.使用伯氨喹和葡萄糖-6-磷酸脱氢酶缺乏症检测:疟疾流行国家的不同政策和做法。
PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006230. doi: 10.1371/journal.pntd.0006230. eCollection 2018 Apr.
5
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.在间日疟原虫抗复发治疗中禁用伯氨喹:G6PD 缺乏症和细胞色素 P-450 2D6 多态性的问题。
Malar J. 2018 Jan 22;17(1):42. doi: 10.1186/s12936-018-2190-z.
6
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.在埃塞俄比亚比较蒿甲醚-本芴醇与氯喹联合或不联合伯氨喹治疗间日疟原虫感染的疗效:一项随机对照试验。
PLoS Med. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299. eCollection 2017 May.
7
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.非洲遗传多样性:对细胞色素 P450 介导的药物代谢和药物开发的影响。
EBioMedicine. 2017 Mar;17:67-74. doi: 10.1016/j.ebiom.2017.02.017. Epub 2017 Feb 20.
8
Management of relapsing Plasmodium vivax malaria.复发性间日疟的管理
Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31.
9
Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination.间日疟原虫和恶性疟原虫共同流行的不同传播动态:对疟疾控制和消除的影响
PLoS Negl Trop Dis. 2015 May 7;9(5):e0003739. doi: 10.1371/journal.pntd.0003739. eCollection 2015 May.
10
Glucose-6-phosphate dehydrogenase deficiency among malaria suspects attending Gambella hospital, southwest Ethiopia.埃塞俄比亚西南部甘贝拉医院疟疾疑似患者中的葡萄糖-6-磷酸脱氢酶缺乏症
Malar J. 2014 Nov 18;13:438. doi: 10.1186/1475-2875-13-438.

病例报告:在埃塞俄比亚甘贝拉,伯氨喹根治疟疾失败。

Case Report: Primaquine Failure for Radical Cure of Malaria in Gambella, Ethiopia.

机构信息

1Centers for National Health Development Ethiopia, Addis Ababa, Ethiopia.

2Laboratory Department, Saint Paulos Hospital, Millennium Collage, Addis Ababa, Ethiopia.

出版信息

Am J Trop Med Hyg. 2020 Jul;103(1):415-420. doi: 10.4269/ajtmh.19-0890. Epub 2020 May 7.

DOI:10.4269/ajtmh.19-0890
PMID:32394882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7356453/
Abstract

Failures of primaquine for the treatment of relapsed malaria is a serious challenge to malaria elimination in Ethiopia, where accounts for up to 40% of malaria infections. We report here occurrence of a total of 15 episodes of primaquine treatment failure for radical cure in three historical malaria patients from Gambella, Ethiopia, during 8-16 months of follow-up in 1985-1987. The total primaquine doses received were 17.5 mg/kg, 25.8 mg/kg, and 35.8 mg/kg, respectively. These total doses are much higher than in previous reports of patients with treatment failure in Ethiopia and East Africa. The possibility of new infection was excluded for these cases as the treatment and follow-up were carried out in Addis Ababa, a malaria-free city. Recrudescences were unlikely, considering the short duration pattern of the recurrences. The cytochrome P450 2D6 (CYP2D6) status for these patients is unknown, but polymorphisms have been described in Ethiopia and may have contributed to primaquine treatment failures. It is suggested that further studies be carried out in Ethiopia to determine the prevalence and distribution of primaquine treatment failures in different ethnic groups, considering the impact of CYP2D6 polymorphisms and the potential value of increasing the primaquine dose to avoid relapse.

摘要

在埃塞俄比亚,由于伯氨喹用于治疗复发疟疾的失败率很高,对疟疾的消除构成了严重挑战,伯氨喹的失败率高达疟疾感染的 40%。我们在此报告了在 1985 年至 1987 年的 8-16 个月随访期间,来自埃塞俄比亚甘贝拉的 3 名历史疟疾患者共发生了 15 例伯氨喹根治治疗失败的情况。他们分别接受了 17.5mg/kg、25.8mg/kg 和 35.8mg/kg 的总剂量。这些总剂量远远高于此前埃塞俄比亚和东非报道的治疗失败患者的剂量。由于治疗和随访是在没有疟疾的亚的斯亚贝巴进行的,因此可以排除这些病例再次感染的可能性。考虑到复发的持续时间短,不太可能是复燃。这些患者的细胞色素 P450 2D6(CYP2D6)状态未知,但在埃塞俄比亚已经描述了其多态性,可能导致了伯氨喹治疗失败。鉴于 CYP2D6 多态性的影响及其增加伯氨喹剂量以避免复发的潜在价值,建议在埃塞俄比亚开展进一步的研究,以确定不同族群中伯氨喹治疗失败的流行率和分布情况。